/Revvity%20Inc_%20logo%20on%20phone%20and%20site%20by-%20T_Schneier%20via%20Shutterstock.jpg)
Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading provider of health sciences solutions, technologies, and diagnostic services. Valued at $14.7 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas. The leading research and diagnostic firm is expected to announce its fiscal fourth-quarter earnings for 2024 before the market opens on Friday, Jan. 31.
Ahead of the event, analysts expect RVTY to report a profit of $1.36 per share on a diluted basis, up 8.8% from $1.25 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
For the full year, analysts expect RVTY to report EPS of $4.84, up 4.1% from $4.65 in fiscal 2023. Its EPS is expected to rise 4.1% year over year to $5.04 in fiscal 2025.
RVTY stock has underperformed the S&P 500’s ($SPX) 22.1% gains over the past 52 weeks, with shares up 9% during this period. However, it outperformed the Health Care Select Sector SPDR Fund’s (XLV) marginal losses over the same time frame.
RVTY's struggles stem from poorly executed acquisitions, ineffective resource allocation, and missed post-pandemic opportunities, coupled with reduced demand from pharma customers, leading to flat growth and deteriorating financials.
On Nov. 4, RVTY shares closed up more than 3% after reporting its Q3 results. Its adjusted revenue of $684 million, up 2% year over year. The company’s adjusted EPS increased 8.5% year over year to $1.28. RVTY expects full-year adjusted EPS to be between $4.83 and $4.87, and expects revenue to be between $2.75 billion and $2.77 billion.
Analysts’ consensus opinion on RVTY stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 17 analysts covering the stock, nine advise a “Strong Buy” rating, one suggests a “Moderate Buy,” and seven give a “Hold.” RVTY’s average analyst price target is $133.94, indicating a potential upside of 10.9% from the current levels.
